Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-09-09
DOI
10.1038/srep32887
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of short hairpin RNA-mediated adiponectin/Acrp30 down-regulation on insulin signaling and glucose uptake in the 3T3-L1 adipocytes
- (2014) K. Li et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Subcutaneous adipose tissue zinc-α2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity
- (2014) Miroslav Balaz et al. Obesity
- Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
- (2013) S. Goring et al. DIABETES OBESITY & METABOLISM
- Inhibition of preadipocyte differentiation and adipogenesis by zinc-α2-glycoprotein treatment in 3T3-L1 cells
- (2013) Hui-Juan Zhu et al. Journal of Diabetes Investigation
- Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
- (2012) L. Chen et al. CURRENT MOLECULAR MEDICINE
- Zinc- 2-Glycoprotein Is Associated With Insulin Resistance in Humans and Is Regulated by Hyperglycemia, Hyperinsulinemia, or Liraglutide Administration: Cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes
- (2012) M. Yang et al. DIABETES CARE
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Circulating Sfrp5 Is a Signature of Obesity-Related Metabolic Disorders and Is Regulated by Glucose and Liraglutide in Humans
- (2012) Wenjing Hu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
- (2012) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Contrasts between the effects of zinc-α2-glycoprotein, a putative β3/2-adrenoceptor agonist and the β3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice
- (2012) Edward T Wargent et al. JOURNAL OF ENDOCRINOLOGY
- Zinc-Alpha 2-Glycoprotein Gene Expression in Adipose Tissue Is Related with Insulin Resistance and Lipolytic Genes in Morbidly Obese Patients
- (2012) Lourdes Garrido-Sánchez et al. PLoS One
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
- (2011) James F. List et al. KIDNEY INTERNATIONAL
- The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose–lipid metabolism in vitro
- (2011) Ke Li et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Studies on the antiobesity effect of zinc-α2-glycoprotein in the ob/ob mouse
- (2010) S T Russell et al. INTERNATIONAL JOURNAL OF OBESITY
- Zinc-α2-glycoprotein: an adipokine modulator of body fat mass?
- (2010) C Bing et al. INTERNATIONAL JOURNAL OF OBESITY
- The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity
- (2009) T. Mracek et al. CLINICAL ENDOCRINOLOGY
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
- (2009) Iskandar Idris et al. DIABETES OBESITY & METABOLISM
- Antidiabetic Properties of Zinc-α2-Glycoprotein inob/obMice
- (2009) Steven T. Russell et al. ENDOCRINOLOGY
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search